Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights

October 18, 2024

Sponsored By

Why are biotech investors so interested in autoimmune disease? Who is behind the telehealth GLP-1 boom? And what were our favorite moments from the STAT Summit this week?

We talk about all that and more on this week's episode of "The Readout LOUD," STAT's biotech podcast. We chat about investors' interest in using CAR-T to treat autoimmune conditions, the latest developments with the supply of Eli Lilly's blockbuster weight loss drug, and the invisible medical groups behind the dozens of telehealth platforms providing GLP-1 drugs.

We also look back at our two-day summit that brought together biopharma executives, scientists, policymakers and patient advocates for conversations about the future of health care.

LISTEN NOW

For more on the autoimmune gold rush, go here; for more on issues surrounding the supply of Lilly's GLP-1 drug, go here; for more on the medical groups behind telehealth companies' GLP-1 offerings, go here; and to learn more about Alnylam CEO Yvonne Greenstreet's conversation at the STAT Summit, go here.